Nilsine Partners’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Nilsine Partners’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23M	Buy	554,955 +526,898	+1,878%	+$21.2M	1.6%	11
2026 Q2	$1.07M	Buy	28,057 +937	+3%	+$32.6K	0.07%	221
2026 Q1	$908K	Buy	+27,120	New	+$927K	0.07%	222
2023 Q2	–	Sell	-43,186	Closed	-$1.13M	–	349
2023 Q1	$1.13M	Buy	+43,186	New	+$1.16M	0.18%	152

Other funds holding FTXH

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.38B AUM 24% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Daymark Wealth Partners Cincinnati, Ohio $4.41B AUM 22.52% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Spire Wealth Management Mclean, Virginia $3.27B AUM 30.11% 1-Year Est. Return

Cyndeo Wealth Partners St. Petersburg, Florida $2.21B AUM 17.29% 1-Year Est. Return

Nilsine Partners's FTXH Position: Q3 2026 in Review

Nilsine Partners increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 1,878% in Q3 2026, buying an estimated $21.2M and bringing the position to 554,955 shares worth $23M. The position accounts for 1.6% of the portfolio, ranked #11.

Nilsine Partners first reported a position in FTXH in Q1 2023 and has held it in 4 quarters since. 28 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

Nilsine Partners held 554,955 shares of First Trust Nasdaq Pharmaceuticals ETF worth $23M as of Q3 2026.
Nilsine Partners bought 526,898 First Trust Nasdaq Pharmaceuticals ETF shares in Q3 2026, an estimated $21.2M.
First Trust Nasdaq Pharmaceuticals ETF made up 1.6% of Nilsine Partners's portfolio in Q3 2026, its #11 holding.
Nilsine Partners first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2023 and has held it in 4 quarters since.
28 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on Nilsine Partners's 13F filing for Q3 2026, filed 2 Nov 2026.